Newcastle startup Invenirex raised £2 million in seed funding to commercialize 'nanites' — programmable DNA microstructures that enable enzyme‑free nucleic acid detection with high sensitivity in about 45 minutes — and plans a research‑use instrument launch. The company is targeting oncology and sepsis diagnostics and vaccine‑manufacturing QC. Separately, Laigo Bio closed a €11.5 million seed round to develop E3 ubiquitin ligase‑based targeted protein degradation approaches. Both financings underscore investor interest in platform technologies that promise step‑change improvements in diagnostics and modality innovation.